News
Far from ‘boxed in’: The innovative design transforming at-home testing

Alexander Parker is head of wellness at packaging design and manufacturing company, Burgopak.
Burgopak is a world leader in design innovation, with a 25-year-history spanning entertainment, consumer tech and now health diagnostics, including an expanding range of at-home hormone and fertility testing kits.
We speak to Alexander to discover what goes into designing robust, functional but engaging packaging and the sometimes surprising considerations that can make or break a product.
Hi Alexander. Please tell us about your role at Burgopak.
My role is about driving our growth and direction in the healthcare and wellness space, which in practice means everything from packaging to client engagement, to partnerships, to developing the team.
I also sit on the company management committee and help manage our IP portfolio.
Before stepping into this role, I spent 20 years as a designer, 15 of them as head of design – so I bring a hands-on understanding of what it takes to deliver great packaging.
At-home test kits require the user to perform a medical procedure alone, without professional support.
How does that inform your design approach?
It’s a key pillar of a project, heavily influenced by the product and its intended use.
In the case of a test kit being used to collect a sample specimen and return it to a lab, there’s often plenty of opportunity for packaging to help or hinder the process and experience.
There are layers to effective packaging.
● Structure – Physical interventions through the packaging.
● Artwork – The visual identity, messaging and instructions across the pack and instructions for use.
● Signalling – Sometimes-undervalued but what signals are communicated through the packaging – how this makes the user feel about the product, the company behind it and the task at hand.
Careful design of the instructions for use is universally appreciated and often a regulatory requirement.
However, the pack structure and artwork should also work together to communicate a clear user journey.
This could include presenting components in the order they’re used, aligning the pack layout with the IFU steps (Prepare>Test>Return), making the IFU immediately visible as a hero component.
We can also introduce physical aids, like collection tube stands, to help during the sampling process.
The packaging is often used in the return of the sample to a lab so this needs to be considered and intuitively designed.
The structure, materials and artwork are all communicating something to the user.
You want to reassure the user by signalling care, efficacy, trust and in the case of a paid product, value.
In your mind, compare these two pack examples.
One a simple carton with a sea of components loosely filled and rattling around inside. Poor quality print and seemingly damaged in the post.
Contrast that with a suitably robust piece of packaging, with the components arranged and labelled into steps 1, 2, 3.
They might both work, but you can imagine the second building a reassured user experience.
How often do you encounter brands that haven’t thought about the emotional and potentially anxiety-inducing moment of opening a testing kit, and what’s the first thing you fix?
Thankfully it’s not too often, in our case at least.
I think we tend to attract customers who sense there’s more to packaging than just being a container or functionally driven.
The start of a project for us is building a brief with the customer and aligning on values for the packaging – what we want people to feel when opening or using it – as well as defining the technical requirements.
So, if there’s going to be an early fix it’ll probably be here, establishing the emotional intent.
How has the rise in social media ‘unboxing’ videos and product reviews changed what you do?
Is there a tension between designing for social media shareability and designing for the privacy women often want around health testing?
I don’t think there has to be a tension, provided everyone is clear on what the goals of the packaging are, and they are aligned with the product type and its use.
We can’t influence the results of a test or the positive or negative emotional significance it has in someone’s life.
What we can do is design packaging that offers the best possible user experience.
If there’s a shareable moment at the end, packaging might be a prop within a photo or video. But equally it might be a very private experience.
If it’s a test offering a diagnosis or insights into a health condition – you can conceive of a range of emotional outcomes. As you could imagine for certain fertility products too.
The design needs to acknowledge all these possibilities in its structural design, visual identity and the signals they communicate.
For women using a fertility or hormone test, perceived quality signals trust.
How do you stop sustainable choices from reading as cheap?
Do the essentials well, look for small interventions that add value and use attention to detail to signal that the care taken over the packaging, and sustainability, extends to the user.
Material choice is incredibly important.
In the case of paperboard quality can be a spectrum so it’s important to take the time to find and qualify the right one.
One that offers the necessary performance characteristics, is verifiably from responsibly managed forests such as through FSC/PEFC, and from a mill whose activities are aligned with your sustainability targets.
Take care over the design of each touch point and detail. A fitment that holds a device should neatly cradle it. A closure should be intuitive to open and work every time.
If the pack is meant to stand up, then the proportions should be optimised to facilitate that. It’s attention to the details that’s important.
Print quality will have a big impact on perception, not just the messaging or visual identity it renders. If the print quality is poor, then it devalues the product.
Doing it well doesn’t mean using material resources – it’s careful vendor selection and quality assurance.
For some responsible premiumisation you can introduce embossing or debossing details to the artwork, a tactile three-dimensional finish.
This details-led approach is valuable across all packaging but if sustainability is driving a reduction to the essentials, then there is a heightened importance to the execution of what is left.
As at-home health testing moves into NHS and public health contexts, what does good packaging look like when the brief is scale and cost rather than aspiration?
Scale and cost often feature very heavily in the success of projects outside of these settings, so there are parallels between the public and private, but with greater imperative to strip things back.
What is important to understand is success is not a piece of packaging in isolation. It’s efficiency, kitting, quality, distribution, tracking, data management across all activities and partners. Packaging is one part of the bigger picture.
Central to all of this is the need for it to reliably and consistently encourage the correct use of the kit through structure, artwork and instructions.
It is materially efficient and from a robust agile supply chain.
Assembly and kitting might be automated so it will be designed for those production lines or in conjunction with the equipment development.
It is compliant with all transport regulations and the most cost-efficient postal streams to the patient and from them back to the lab.
So, what does good packaging look like? It’s the design that efficiently offers the best patient user experience through a robust, reliable, scalable supply chain.
How do you make the business case for investing in packaging design before the product itself is ready to market?
There’s an opportunity cost.
Packaging has the potential to be a valuable asset when someone invests time and resources into coherent design and development. By starting too late or under resourcing the process you risk having packaging that’s a commercial pain point.
At the earliest opportunity, you at least want to be selecting your packaging partners and have a clear understanding of the development timeline and milestones – structural design, prototyping, stakeholder feedback, artwork/labelling development, regulatory milestones, transit testing, stability testing, wetproofing, manufacturing, delivery.
You must complete these steps before your product can go to market.
What’s the cost to you of delaying launch because you didn’t get packaging underway sooner?
You need to spend time creating packaging that elevates your brand and is a marketing asset that works across ecommerce, retail, advertising, social media.
Engage with the other supply chain stakeholders.
One example would be involving kitting partners in the process to validate and input on packaging improvements. If it’s expensive to kit, your cost of goods go up and if it’s slow to kit you might not have a scalable solution.
You may also find packaging insights influence product decisions.
If you are defining components for a test kit, factor in that larger devices might in turn increase pack size and eventually incur higher shipping costs.
You might work with a device manufacturer on how a USB cable is wound so the packaging volume can be decreased – another potential packaging and shipping cost reduction.
Transit testing and design improvements ensure that products arrive in acceptable condition – reducing costs associated with replacements, damaged reputation and potentially the loss of repeat purchases.
Packaging done well is that opportunity realised – it’s value demonstrated across sales, marketing and operations.
For a founding team approaching a packaging partner for the first time, what does a genuinely useful brief contain, what do most brands leave out, and how much does coming in underprepared add to the timeline and cost?
At Burgopak we build a brief together with the customer and that usually happens in a few stages.
The initial conversation is a chance to learn more about each other, make sure we’re a good fit for one another and the project.
We like to learn more about you, your product, how it’s used and some headline information around timelines, volumes, budget, your packaging ambitions and likes/dislikes.
We explain what we do and how we typically work. This really is the kick-off point – the goal at the end of this stage is being excited to be working together on a project that looks technically and commercially feasible.
In the next stage we build-out a brief capturing the technical and brand-led requirements of the packaging.
It will cover product details, brand & experience, sales & delivery channels, fulfilment and distribution, budget and timelines, compliance and regulations.
The exact questions will vary by product and project, but they span those areas.
From this we can build the project plan – and this might involve working towards answers that aren’t yet defined.
It seems obvious, but knowing exactly what needs to be packaged is fundamental – the product, peripherals – and this can be one of the common missing puzzle pieces.
You can design a container to hold ‘something’.
But when you know exactly what the product is – its size, shape, weight, how it’s used – you can design a piece of packaging that is maximally efficient and effective in elevating the total product experience.
The risk to a successful project is not so much under preparedness at the start – we’re here to help build the brief and a realistic project plan – it’s a loss of momentum through the process.
The packager and the client must work together.
We can be very efficient and agile in doing the work but there’s also the responsibility from the client to keep momentum through rounds of feedback, coordinating product samples or technical drawings and so on.
If there’s a finite timeline and repeated delays within it there can come a crunch point – when delivery dates are pushed out or potentially avoidable compromises made.
Come prepared to collaborate on the brief – but know that the founding teams who get the best outcomes are the ones who stay engaged and keep momentum through the whole process, not just the kick-off.
Learn more about Burgopak at burgopak.com
Entrepreneur
Korea’s Femtech Industry Goes Global as Vespexx Hosts Korea Femtech Summit 2026

From AI embryo analysis in India to couples fertility care launching in the US, Korea’s women’s health startups are going global, and US investors are taking notice.
Vespexx, the femtech company behind couples preconception health platform Soonr, hosted Korea Femtech Summit 2026 on June 30 in Seoul, convening founders, clinicians, and investors from Korea, Singapore, Canada, and Japan to map the global expansion of women’s health technology.
A panel moderated by Kakao Ventures’ Jade Chung, an OB/GYN-turned-investor, captured the summit’s central theme: Korean startups taking on the world. On stage were three companies already building well beyond Korea. Vespexx, led by Co-CEO Scarlett Joowon Jung, is entering the US with Soonr; Kai Health, founded by CEO Hyejun Lee, has deployed its AI embryo-analysis software across more than 120 fertility clinics in India; and Endo Health, represented by the Head of Design Karlie Hyeonjeong Koo, has built Glow, an AI coaching app whose user base is 98% women and which is backed by US investors including a16z. Together they discussed what it takes for Korean startups to compete globally, where AI creates a real edge, and whether “K-femtech” can follow the path of K-beauty onto the world stage.

The program spanned the full arc of women’s health technology. Lindsay Davis, founder of FemTech Association Asia, opened with a look at where Asia’s femtech stands today. Dr. Juhye Lee of Ewha Womans University Mokdong Hospital offered a clinician’s view of how patient needs are shifting, arguing that women’s health is expanding beyond pregnancy and treatment toward care across the entire life course. Boram Bae, Head of Digital Health PM Part at Samsung Electronics spoke to how a consumer platform at global scale can connect women’s everyday health data with life-stage care. And Rimi Lee, head of the Femtech Center at KOSDAQ-listed diagnostics company Sugentech, traced the evolution of hormone testing from results read by eye to AI-assisted analysis, and pointed toward wearable continuous hormone monitoring as the next frontier.
Vespexx Co-CEO Scarlett Joowon Jung presented the company’s “dyadic health” approach on their ‘Soonr’ app, which brings both partners into fertility and preconception care rather than tracking a woman’s data alone, an approach validated by their legacy product, Signaling’s 800,000 users across Asia, as the company prepares for US launch.
The summit also featured Rachel Bartholomew, the Canadian founder of Hyivy Health and Femtech Across Borders, who built her pelvic-health company, and Megumi Kimura of the Japan Women’s Health Innovation Association, who outlined the investment and business models driving Japan’s fast-growing femtech market.

At the summit, Vespexx also announced the launch of Femtech Korea, an industry network intended to connect Korean femtech companies with global markets and partners, and to serve as a bridge for cross-border collaboration.
“Korea has world-class healthcare technology, but femtech has been one of its best-kept secrets,” said Scarlett Joowon Jung, Co-CEO of Vespexx. “The companies on this stage are proof that’s changing. We’re not just building for Korea anymore, we’re building for the world, and we want US partners and investors to be part of that.”
Korea Femtech Summit 2026 was hosted by Vespexx and co-hosted by FemTech Association Asia. The summit was sponsored by Sugentech, with additional support from Innerness and Octolabs.
About Vespexx
Vespexx is a Korean femtech startup and subsidiary of KOSDAQ-listed biotech Sugentech. The company operates Soonr Health, a couples-focused preconception health platform, and its earlier product Signaling has accumulated over 800,000 users. Vespexx is currently expanding into the North American market.
About Femtech Association Asia
FemTech Association Asia is the region’s first and largest specialist advisory and industry network for founders, investors, corporate partners, and ecosystem contributors, with a core focus on improving women’s health through technology solutions.
News
Don’t miss HTW’s upcoming deep dive into health AI

Our sister publication Health Tech World brings its first live event to London this summer, gathering the people building, buying and regulating healthcare AI for a single afternoon. With a full line-up confirmed and two months to go, tickets are open now, and this first edition is one to book early.
Health Tech World Live, the debut live event from FemTech World’s sister title Health Tech World, makes its first appearance on Friday 21 August, bringing clinicians, founders, developers, NHS commissioners and investors together at Teesside University London in Stratford for an afternoon on where healthcare AI goes next. The programme is confirmed, and with two months to go, it is worth booking your place while the diary is still clear.
The line-up for this first edition reads like a who’s-who of UK health AI. Speakers include Dr James Harmsworth King, Chief Medical Strategy Officer at Numan, fresh from the MHRA’s AI Airlock; Dr Sonia Szamocki, founder and CEO of 01Health; Hugo Dragonetti of NHS London Procurement Partnership; Mikael Kågebäck, CTO at Sleep Cycle; Max Gattlin, Commercial Director at X-on Health; and Marcus Vass, Head of Digital Health at Osborne Clarke, with proceedings chaired by Alastair MacColl.
Across six sessions, the afternoon moves from scaling specialist care and smarter NHS procurement, through responsible delivery and consumer AI, to fair access to GP care and the regulation underpinning all of it. Between the talks, delegates get time with the speakers and the Health Tech World editorial team, the kind of access that is hard to come by anywhere else.
It is shaping up to be one of the summer’s standout dates in health tech, and a launch worth being part of from the start. If you are planning to be there, now is the time to get it booked.
The future of healthcare AI: strategies, opportunities and vital insights
When: Friday 21 August 2026, 12 noon to 4pm
Where: Teesside University London Campus, Queen Elizabeth Olympic Park, 14 East Bay Lane, London, E15 2GW
Tickets: £99

Menopause
Immunotherapy may temporarily restore fertility in premature menopause

Immunotherapy may temporarily restore fertility in women with autoimmune premature ovarian insufficiency, a pilot study suggests.
Three of the 10 women who received treatment later gave birth to healthy babies.
Premature ovarian insufficiency, or POI, affects just over three per cent of women worldwide and occurs when the ovaries stop functioning before the age of 40.
The condition significantly reduces fertility and can have several causes, including autoimmune processes and genetics.
Researchers at Karolinska Institutet examined whether immunotherapy could make the ovaries temporarily responsive to hormonal stimulation in women with POI caused by autoimmunity.
The study included 12 women aged between 18 and 35 with autoimmune POI.
Two withdrew before treatment began. The remaining 10 underwent ovarian hormone stimulation before receiving rituximab and again four to six months after treatment.
Rituximab is an approved and well-established medicine used to treat several autoimmune conditions and cancers.
None of the women responded to ovarian stimulation before receiving the drug.
After treatment, six developed follicles that made it possible to retrieve eggs in response to ovarian stimulation.
Follicles are small sacs within the ovaries where eggs develop.
Professor Angelica Lindén Hirschberg, the study’s first author and a professor at Karolinska Institutet’s Department of Women’s and Children’s Health, said: “The results show that in some women there remains an egg reserve that can be activated when the autoimmune process is suppressed.”
In five women, mature eggs could be frozen or fertilised.
Three later had embryos transferred and all three gave birth to healthy babies.
For safety reasons, the embryo transfers took place no earlier than one year after treatment.
One serious side effect was reported and was linked to the hormone stimulation rather than the immunotherapy.
Women with autoimmune POI commonly have other autoimmune diseases.
All six women who responded to the treatment also had autoimmune Addison’s disease, a condition in which the immune system destroys the adrenal glands.
The study was a proof-of-concept investigation without a control group and involved a small number of participants, meaning the findings must be interpreted cautiously.
A proof-of-concept study is an early investigation designed to assess whether an approach could work before it is tested more widely.
Professor Lindén Hirschberg said: “This is a first step. To determine whether the method is effective and safe, larger, randomised studies are required.”
The research team has launched a larger randomised study.
The work was carried out by researchers at Karolinska Institutet, Karolinska University Hospital and the University of Bergen.
It was funded by organisations including the Swedish Research Council, the Knut and Alice Wallenberg Foundation, the Novo Nordisk Foundation and Region Stockholm.
The researchers reported no conflicts of interest.
POI is also linked to long-term health risks caused by oestrogen deficiency, including osteoporosis, an increased risk of cardiovascular disease, cognitive decline and poorer mental and sexual wellbeing.
Hormone replacement therapy can relieve menopausal symptoms and reduce many of these risks, but no treatment has been reliably shown to restore fertility in women with POI.
Egg donation was previously the only option for women with the condition who wanted to become pregnant.
Insight4 weeks agoBritish women among angriest in Europe, health survey reveals
Menopause3 weeks agoApple Health adds menopause and perimenopause tracking
News3 weeks agoFemtech World Awards 2026: Winners revealed
News4 weeks agoElation Health acquires EHR startup Aster
Menopause3 weeks agoMenopause workplace toolkit launched to help UK employers support staff
Entrepreneur3 weeks agoWomen’s Health Week Europe 2026 opens pitch applications for mainstage showcase at The Emirates Stadium
News4 weeks agoEndometriosis documentary profiles stars including Marilyn Monroe and Amy Schumer
Mental health4 weeks agoNatural birth pressure harming new mothers’ mental health, research finds






